Characteristics of the total study population (n = 1112)
| Parameter . | n (%) or median (IQR) . |
|---|---|
| Total length of observation, years | 25 700 |
| Total length of observation, ED | 44 800 |
| Baseline FVIII:C, IU/dL | 11.5 (6.0-20.0) |
| Classified into FVIII:C categories, IU/dL | |
| 2-5 | 231 (20.8) |
| 6-10 | 283 (25.4) |
| 11-20 | 345 (31.0) |
| 21-30 | 180 (16.2) |
| 31-40 | 73 (6.6) |
| F8 genotype known | 895 (80.5) |
| Positive family history of inhibitors | 26 (2.3) |
| Ethnicity | |
| White | 1,049 (94.3) |
| African-American | 14 (1.3) |
| Asian | 18 (1.6) |
| Other | 24 (2.2) |
| Unknown | 7 (0.6) |
| Age at the end of follow-up, years | 38 (18-56) |
| Number inhibitors | 59 (5.3) |
| Cumulative ED to factor VIII concentrates | 24 (7-90) |
| Classified into ED categories: | |
| 1-5 | 166 (14.9) |
| 5-10 | 151 (13.6) |
| 10-20 | 200 (18.0) |
| 20-30 | 131 (11.8) |
| 30-50 | 107 (9.6) |
| 50-100 | 156 (14.0) |
| ≥100 | 179 (16.1) |
| Unknown | 22 (2.0) |
| Parameter . | n (%) or median (IQR) . |
|---|---|
| Total length of observation, years | 25 700 |
| Total length of observation, ED | 44 800 |
| Baseline FVIII:C, IU/dL | 11.5 (6.0-20.0) |
| Classified into FVIII:C categories, IU/dL | |
| 2-5 | 231 (20.8) |
| 6-10 | 283 (25.4) |
| 11-20 | 345 (31.0) |
| 21-30 | 180 (16.2) |
| 31-40 | 73 (6.6) |
| F8 genotype known | 895 (80.5) |
| Positive family history of inhibitors | 26 (2.3) |
| Ethnicity | |
| White | 1,049 (94.3) |
| African-American | 14 (1.3) |
| Asian | 18 (1.6) |
| Other | 24 (2.2) |
| Unknown | 7 (0.6) |
| Age at the end of follow-up, years | 38 (18-56) |
| Number inhibitors | 59 (5.3) |
| Cumulative ED to factor VIII concentrates | 24 (7-90) |
| Classified into ED categories: | |
| 1-5 | 166 (14.9) |
| 5-10 | 151 (13.6) |
| 10-20 | 200 (18.0) |
| 20-30 | 131 (11.8) |
| 30-50 | 107 (9.6) |
| 50-100 | 156 (14.0) |
| ≥100 | 179 (16.1) |
| Unknown | 22 (2.0) |
ED, exposure days to factor VIII concentrates.